@letstalkseniorcare: 💊 Rexulti (brexpiprazole) received FDA approval in 2023 to treat agitation associated with dementia due to Alzheimer’s disease. But how can ABA complement medication? 🧠 Rexulti may help reduce agitation, while ABA strategies can help identify triggers, recognize patterns, and teach alternative ways to communicate needs. For example, behavior tracking can help the care team identify situations that lead to agitation and develop proactive strategies to reduce distress. Combining medication with individualized behavioral interventions may support better outcomes and quality of life. The goal? Not simply to reduce behaviors, but to understand the person’s needs and improve their overall well-being. . . . #DementiaCare #ABA #Rexulti #AlzheimersDisease #SeniorCare #PersonCenteredCare #BCBA #LetsTalkSeniorCare #BehaviorAnalysis #AppliedBehaviorAnalysis #OlderAdtuls #DementiaMedications #BehaviorGerontology
